Physalin ACAS# 23027-91-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 23027-91-0 | SDF | Download SDF |
| PubChem ID | 101650336 | Appearance | Powder |
| Formula | C28H30O10 | M.Wt | 526.5 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC12CC(C3(C45C1C(=O)C(O4)(C6C(CCC5(C(=O)O3)O)C7(C(=CC6O)CC=CC7=O)C)O)C)OC(=O)C2=C | ||
| Standard InChIKey | VELDODQHYQSJOF-RKWIMMEGSA-N | ||
| Standard InChI | InChI=1S/C28H30O10/c1-12-21(32)36-17-11-23(12,2)19-20(31)27(35)18-14(24(3)13(10-15(18)29)6-5-7-16(24)30)8-9-26(34)22(33)37-25(17,4)28(19,26)38-27/h5,7,10,14-15,17-19,29,34-35H,1,6,8-9,11H2,2-4H3/t14-,15+,17+,18-,19-,23+,24-,25-,26-,27-,28-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling. 2. Physalin A induces apoptosis via p53-Noxa-mediated ROS generation, and autophagy plays a protective role against apoptosis through p38-NF-κB survival pathway in A375-S2 cells. 3. Physalin A inhibits androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression. |
| Targets | JAK | STAT | Bcl-2/Bax | p53 | ROS | Autophagy | NF-kB | p38MAPK | JNK | ERK | Androgen Receptor |
Physalin A Dilution Calculator
Physalin A Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8993 mL | 9.4967 mL | 18.9934 mL | 37.9867 mL | 47.4834 mL |
| 5 mM | 0.3799 mL | 1.8993 mL | 3.7987 mL | 7.5973 mL | 9.4967 mL |
| 10 mM | 0.1899 mL | 0.9497 mL | 1.8993 mL | 3.7987 mL | 4.7483 mL |
| 50 mM | 0.038 mL | 0.1899 mL | 0.3799 mL | 0.7597 mL | 0.9497 mL |
| 100 mM | 0.019 mL | 0.095 mL | 0.1899 mL | 0.3799 mL | 0.4748 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Neoglycyrol
Catalog No.:BCN2907
CAS No.:23013-84-5
- MPTP hydrochloride
Catalog No.:BCC1778
CAS No.:23007-85-4
- Atazanavir sulfate (BMS-232632-05)
Catalog No.:BCC2114
CAS No.:229975-97-7
- AGN 194310
Catalog No.:BCC5416
CAS No.:229961-45-9
- GW9662
Catalog No.:BCC2260
CAS No.:22978-25-2
- Abn-CBD
Catalog No.:BCC7011
CAS No.:22972-55-0
- Desmethoxycentaureidin
Catalog No.:BCN5077
CAS No.:22934-99-2
- Neferine
Catalog No.:BCN6338
CAS No.:2292-16-2
- Ginkgolic acid C15:1
Catalog No.:BCN2307
CAS No.:22910-60-7
- R 892
Catalog No.:BCC5992
CAS No.:229030-05-1
- TAK-779
Catalog No.:BCC4137
CAS No.:229005-80-5
- 4-Amino-3,5-dichloropyridine
Catalog No.:BCC8679
CAS No.:22889-78-7
- Apelin-36 (rat, mouse)
Catalog No.:BCC5911
CAS No.:230299-95-3
- Terbutaline Sulfate
Catalog No.:BCC4320
CAS No.:23031-32-5
- Z-β-Ala-OH
Catalog No.:BCC3058
CAS No.:2304-94-1
- Z-Asn-OH
Catalog No.:BCC2794
CAS No.:2304-96-3
- Z-Arg(NO2)-OH
Catalog No.:BCC3063
CAS No.:2304-98-5
- Ajugasterone C
Catalog No.:BCN2757
CAS No.:23044-80-6
- Lofepramine
Catalog No.:BCC7402
CAS No.:23047-25-8
- Dihydroconiferyl alcohol
Catalog No.:BCN7047
CAS No.:2305-13-7
- L-AP4
Catalog No.:BCC6550
CAS No.:23052-81-5
- (-)-Sophoranone
Catalog No.:BCN7162
CAS No.:23057-55-8
- Sinensetin
Catalog No.:BCN6356
CAS No.:2306-27-6
- Varenicline Hydrochloride
Catalog No.:BCC4156
CAS No.:230615-23-3
Physalin A induces G2/M phase cell cycle arrest in human non-small cell lung cancer cells: involvement of the p38 MAPK/ROS pathway.[Pubmed:27000859]
Mol Cell Biochem. 2016 Apr;415(1-2):145-55.
Physalin A (PA) is an active withanolide isolated from Physalis alkekengi var. franchetii, a traditional Chinese herbal medicine named Jindenglong, which has long been used for the treatment of sore throat, hepatitis, and tumors in China. In the present study, we firstly investigated the effects of PA on proliferation and cell cycle distribution of the human non-small cell lung cancer (NSCLC) A549 cell line, and the potential mechanisms involved. Here, PA inhibited cell growth in dose- and time-dependent manners. Treatment of A549 cells with 28.4 muM PA for 24 h resulted in approximately 50 % cell death. PA increased the amount of intracellular ROS and the proportion of cells in G2/M. G2/M arrest was attenuated by the addition of ROS scavenger NAC. ERK and P38 were triggered by PA through phosphorylation in a time-dependent manner. The phosphorylation of ERK and P38 were not attenuated by the addition of NAC, but the use of the p38 inhibitor could reduce, at least in part, PA-induced ROS and the proportion of cells in G2/M. PA induces G2/M cell cycle arrest in A549 cells involving in the p38 MAPK/ROS pathway. This study suggests that PA might be a promising therapeutic agent against NSCLC.
Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.[Pubmed:26843613]
Oncotarget. 2016 Feb 23;7(8):9462-76.
The signal transducers and activators of transcription 3 (STAT3) signaling pathway plays critical roles in the pathogenesis and progression of various human cancers, including non-small cell lung cancer (NSCLC). In this study, we aimed to evaluate the therapeutic potential of Physalin A, a bioactive withanolide derived from Physalis alkekengi var. francheti used in traditional Chinese medicine, was evaluated in human NSCLC cells. Its and determined whether it effect oninhibited both constitutive and induced STAT3 activity, through repressing the phosphorylation levels of JAK2 and JAK3, resulting in anti-proliferation and pro-apoptotic effects on NSCLC cells was also determined, and. theThe antitumor effects of Physalin A were also validated usingin an in vivo mouse xenograft models of NSCLC cells. Physalin A had anti-proliferative and pro-apoptotic effects in NSCLC cells with constitutively activated STAT3; it also suppressed both constitutive and induced STAT3 activity by modulating the phosphorylation of JAK2 and JAK3. Furthermore, Physalin A abrogated the nuclear translocation and transcriptional activity of STAT3, thereby decreasing the expression levels of STAT3, its target genes, such as Bcl-2 and XIAP. Knockdown of STAT3 expression by small interfering RNA (siRNA) significantly enhanced the pro-apoptotic effects of Physalin A in NSCLC cells. Moreover, Physalin A significantly suppressed tumor xenograft growth. Thus, as an inhibitor of JAK2/3-STAT3 signaling, Physalin A, has potent anti-tumor activities, which may facilitate the development of a therapeutic strategy for treating NSCLC.
Physalin A induces apoptosis via p53-Noxa-mediated ROS generation, and autophagy plays a protective role against apoptosis through p38-NF-kappaB survival pathway in A375-S2 cells.[Pubmed:23684722]
J Ethnopharmacol. 2013 Jul 9;148(2):544-55.
ETHNOPHARMACOLOGICAL RELEVANCE: Physalin A is a bioactive withanolide isolated from natural plant Physalis alkekengi L. var. franchetii (Mast.) Makino, a traditional Chinese herbal medicine named Jindenglong which has long been used for the treatment of cough, sore throat, hepatitis, eczema, dysuria and tumors in China. AIM OF THE STUDY: Based on the previous study that Physalin A induced cytotoxic effect in human melanoma A375-S2 cells, this study was designed to further illustrate the molecular mechanisms underlying. MATERIALS AND METHODS: Cell viability was evaluated in A375-S2 cells by MTT assay, and the mechanisms involved in Physalin A-induced A375-S2 cell death were investigated by phase contrast microscopy and fluorescence microscopy, siRNA transfection, flow cytometry and western blot analysis. RESULTS: We demonstrated that Physalin A decreased the proportion of viable A375-S2 cells in a time- and dose-dependent manner, and exposure of A375-S2 cells to Physalin A led to both apoptosis and autophagy. Moreover, Physalin A-induced apoptosis was triggered by activation of p53-Noxa pathway and intracellular reactive oxygen species (ROS) generation. The administration of ROS scavengers NAC and GSH resulted in the complete inhibition of Physalin A-induced ROS generation and apoptosis. Application of p53 inhibitor PFT-alpha or transfection with Noxa-siRNA could also lead to the same results. Autophagy, demonstrated by the punctuate distribution of monodansylcadaverine staining, as well as the change of LC3-II/LC3-I proportion and Beclin 1 activation, played a protective role against apoptosis via up-regulation of the p38-NF-kappaB survival pathway in A375-S2 cells. Additionally, inhibition of autophagy by the specific autophagic inhibitor 3MA or blocking the p38-NF-kappaB pathway with p38 inhibitor SB203580 or NF-kappaB inhibitor PDTC obviously promoted Physalin A-induced apoptosis. CONCLUSIONS: Physalin A induced apoptotic cell death via p53-Noxa-mediated ROS generation, and autophagy played a protective role against apoptosis through up-regulating the p38-NF-kappaB survival pathway in A375-S2 cells. These results stated the possibility that Physalin A would be a potential agent for the treatment of melanoma in the future.
Physalins A and B inhibit androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression.[Pubmed:21963499]
Biol Pharm Bull. 2011;34(10):1584-8.
Androgen deprivation therapy is a common treatment strategy for advanced prostate cancer. Though effective initially, the tumor often progresses to androgen independent stage in most patients eventually after a period of remission. One of the key factors of development of resistance is reflected in expression of androgen receptor (AR). In this study, we showed that two natural compounds, physalins A and B, both secosteriods from Physalisalkekengi var. franchetii, significantly inhibited the growth of two androgen-independent cell lines CWR22Rv1 and C42B, induced apoptosis via c-Jun N-terminal kinase (JNK) and/or extracellular signal-regulated kinase (ERK) activation, and decreased AR expression. In addition, physalins A and B down-regulated the expression of prostate specific antigen (PSA) in C42B cells which is a target gene of AR. Our results suggest that Physalin A and B might be useful agents in preventing the growth of androgen-independent prostate cancer (AI-PCa).
